tuberculous peritonitis

Reading File
Finding Sources
Finding Sources
Searching PubMed

tuberculous peritonitis diagnosis treatment

Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
I now have comprehensive information from multiple authoritative sources. Let me compile the full answer.

Tuberculous Peritonitis

Overview

Tuberculous (TB) peritonitis is a form of extrapulmonary tuberculosis involving the peritoneal cavity. It accounts for about 0.5% of new TB cases and is the sixth most common site of extrapulmonary TB. Globally it is more prevalent in resource-poor countries, but incidence is rising in resource-rich countries due to immigration and immunosuppression. The abdomen is involved in approximately 11% of all extrapulmonary TB cases, with the peritoneum affected in 50-80% of abdominal TB cases.
Risk factors: HIV infection, cirrhosis, diabetes mellitus, underlying malignancy, and immunosuppression.

Pathogenesis

TB reaches the peritoneum by several routes:
  1. Direct spread - from ruptured mesenteric lymph nodes (typically draining the ileocaecal region), intraabdominal organs, or fallopian tubes (genital TB in women)
  2. Hematogenous seeding - most often from miliary TB, occasionally from cavitating pulmonary TB
  3. Swallowed sputum - seeding via the gastrointestinal tract
Only one-third of patients with peritoneal TB have clinical or radiographic evidence of pulmonary disease at the time of presentation.

Morphological Forms

There are three recognised patterns:
FormFrequencyFeatures
Wet / ascitic~90%Generalised or loculated ascites; multiple tubercle deposits on both peritoneal layers
Dry / plastic / fibroticLess commonFibrotic fixed loops of bowel and omentum matted together; no ascites; may cause subacute intestinal obstruction
MixedVariableCombination of fibrosis and loculated fluid

Clinical Features

Presentation is characteristically insidious, with symptoms present for weeks to months before diagnosis:
  • Abdominal pain and distension
  • Low-grade fever and night sweats
  • Weight loss and anorexia
  • Malaise
Abdominal tenderness is present in fewer than half of patients. Ascites is common in the wet form. An important diagnostic trap: TB peritonitis may present as a pelvic mass with elevated CA-125, closely mimicking metastatic ovarian cancer.
The condition may also present as acute peritonitis that is clinically indistinguishable from acute bacterial peritonitis.

Diagnosis

Ascitic Fluid Analysis

The typical profile of TB ascitic fluid:
ParameterFinding
AppearanceStraw-coloured exudate
Protein>25-30 g/L (high)
Serum-to-ascites albumin gradient (SAAG)<1.1 g/dL (non-portal hypertension)
WBC>500/mL
DifferentialLymphocytic predominance (>40-70%)
AFB smearPositive in <3% of cases
AFB cultureHigher yield but takes 4-8 weeks
Key diagnostic tests:
  • Adenosine deaminase (ADA) in ascitic fluid - elevated in TB peritonitis; high sensitivity and specificity for distinguishing TB from peritoneal carcinomatosis. Caution: false negatives in HIV or cirrhosis; false positives in malignant ascites.
  • Ascitic fluid PCR (Xpert MTB/RIF) - highly sensitive and specific; rapid result
  • ELISPOT / interferon-gamma release assay (IGRA) - value in extrapulmonary TB still being established
  • QuantiFERON-Gold - poor test characteristics for active TB peritonitis, especially in BCG-vaccinated populations

Imaging

  • Ultrasound / CT scan - detects ascites, mesenteric and retroperitoneal lymphadenopathy, diffuse thickening of peritoneum, mesentery and omentum. CT may show a "wet" peritoneal pattern or matted bowel loops (dry form).

Definitive Diagnosis

  • Laparoscopy with peritoneal biopsy - nearly 100% sensitive; reveals scattered whitish peritoneal nodules (tubercles); biopsy shows caseating granulomas in >90% of cases. This is the gold standard when non-invasive tests are inconclusive.
  • Histopathology - caseating granulomas distinguish TB from other causes; also important to differentiate from peritoneal carcinomatosis and fat necrosis of pancreatitis.

Differential Diagnosis

  • Peritoneal carcinomatosis (malignant ascites): most common cause of lymphocytic ascites - 10x more frequent than TB. Peritoneal cytology is positive in >90% of carcinomatosis cases.
  • Ovarian cancer (CA-125 elevation overlap)
  • Crohn disease (intestinal fistulae)
  • Other infectious peritonitis (fungal, parasitic)
  • Primary bacterial peritonitis

Treatment

Standard Regimen (6 months total)

  • Intensive phase (2 months): Isoniazid (H) + Rifampin (R) + Pyrazinamide (Z) + Ethambutol (E) - i.e., HRZE
  • Continuation phase (4 months): Isoniazid + Rifampin (HR)
This is the same regimen used for pulmonary TB. Multidrug resistance may actually be higher for abdominal than for pulmonary TB, so local susceptibility testing is important. Resistant strains may require a longer course and additional agents.
Special considerations:
  • Cirrhotic patients - hepatotoxicity of first-line drugs (particularly isoniazid, rifampin, pyrazinamide) may require modification of the regimen
  • HIV co-infection - antiretroviral therapy (ART) timing must be coordinated with anti-TB therapy
  • Supportive care: nutrition and hydration are important adjuncts

Role of Surgery

Surgery is generally not required but may be needed for complications:
  • Intestinal obstruction (many cases resolve with anti-TB therapy alone)
  • Intestinal fistulae
  • Perforation
Supervision of therapy is critical - erratic treatment leads to emergence of resistant strains and must be overseen by public health personnel and physicians.

Summary of Key Points

  • TB peritonitis is often diagnosed late due to non-specific, insidious presentation
  • The wet (ascitic) form is most common (~90%)
  • Ascitic fluid is an exudate with lymphocytic predominance and elevated protein
  • AFB smear is almost never positive (<3%); culture takes weeks
  • ADA and Xpert MTB/RIF are the most useful rapid non-invasive tests
  • Laparoscopy + biopsy (showing caseating granulomas) is the gold standard
  • Treatment is standard 6-month anti-TB therapy (HRZE x 2 months, then HR x 4 months)
  • The key differential is peritoneal carcinomatosis - cytology resolves most cases

Sources: Sleisenger & Fordtran's Gastrointestinal and Liver Disease; Bailey & Love's Short Practice of Surgery, 28th Ed.; Harrison's Principles of Internal Medicine, 22nd Ed. (2025); Yamada's Textbook of Gastroenterology, 7th Ed.; Frameworks for Internal Medicine

covid

Asking for Preferences

covid

Asking for Preferences

covid

Reading File
Finding Sources
Finding Sources
Searching PubMed

COVID-19 pathophysiology mechanisms SARS-CoV-2

Finding Sources
Finding Sources
This is a shared conversation. Sign in to Orris to start your own chat.